Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

McGill University

$160,000.00

Chemotherapeutic Agents for Inhibiting Protein Synthesis

FY 2010-11

Summary
The process of protein synthesis, or translation, in a normal cell is complex and highly regulated. Under conditions of starvation the process is controlled so that few proteins are synthesized, whereas under conditions favoring growth the process is upregulated. Many experiments indicate that proper control of this process is deregulated in cancer cells. Hence the faster growth rates of cancer cells is associated with elevated levels of protein synthesis since some of the normal regulatory checkpoints on this process have been ablated. Tumor cells therefore become addicted to these higher translation rates and in turn, this becomes a weakness by which to target cancer cells. We have identified a novel inhibitor of translation that shows anticancer activity in pre-clinical mouse models. This compound is a natural product called hippuristanol that is isolated from the coral Isis hippuris. The mechanism of action, its biological target, and a method of synthesis for hippuristanol has been elucidated by us. Herein, we propose experiments to make analogs of hippursitanol to improve its solubility and potency. These new analogs will be tested for their anti-cancer properties, both in cell culture as well as in pre-clinical mouse models. We will also determine if hippuristanol shows antiangiogenic (preventing growth of blood vessels in tumors) properties. Our research strives to provide insight into a basic cellular mechanism whose process is deregulated in human cancers and to develop a therapeutic approach to target this. We are seeking to develop a novel chemotherapeutic agent that targets a novel step in tumor maintenance and would represent a first in class compound.
Program
Proof of Principle Program - Phase I
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
227869
Name
Pelletier Jerry M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Chemotherapeutic Agents for Inhibiting Protein Synthesis
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Anti-Neoplastic; Hippuristanol; Medicinal Chemistry; Translation; Translation Initiation Inhibition
Abstract
The process of protein synthesis, or translation, in a normal cell is complex and highly regulated. Under conditions of starvation the process is controlled so that few proteins are synthesized, whereas under conditions favoring growth the process is upregulated. Many experiments indicate that proper control of this process is deregulated in cancer cells. Hence the faster growth rates of cancer cells is associated with elevated levels of protein synthesis since some of the normal regulatory checkpoints on this process have been ablated. Tumor cells therefore become addicted to these higher translation rates and in turn, this becomes a weakness by which to target cancer cells. We have identified a novel inhibitor of translation that shows anticancer activity in pre-clinical mouse models. This compound is a natural product called hippuristanol that is isolated from the coral Isis hippuris. The mechanism of action, its biological target, and a method of synthesis for hippuristanol has been elucidated by us. Herein, we propose experiments to make analogs of hippursitanol to improve its solubility and potency. These new analogs will be tested for their anti-cancer properties, both in cell culture as well as in pre-clinical mouse models. We will also determine if hippuristanol shows antiangiogenic (preventing growth of blood vessels in tumors) properties. Our research strives to provide insight into a basic cellular mechanism whose process is deregulated in human cancers and to develop a therapeutic approach to target this. We are seeking to develop a novel chemotherapeutic agent that targets a novel step in tumor maintenance and would represent a first in class compound.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pelletier, Jerry M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~
McGill University - $160,000 Grant (2010-11) | Canada Spends